Towards a drug concentration effect relationship for QT prolongation and torsades de pointes

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 1, 2002, Pages 116-126

  Webster, Rob ^a   Leishman, Derek ^a   Walker, Don ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

HERG; Pharmacokinetics pharmacodynamics QT prolongation; Torsades de pointes

Indexed keywords

ASTEMIZOLE; CHLOROQUINE; CIPROFLOXACIN; CISAPRIDE; DOFETILIDE; EBASTINE; ERYTHROMYCIN; FEXOFENADINE; GATIFLOXACIN; GREPAFLOXACIN; HALOFANTRINE; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; IMIPRAMINE; LEVOFLOXACIN; MOXIFLOXACIN; NEUROLEPTIC AGENT; OFLOXACIN; PIMOZIDE; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERTINDOLE; SOTALOL; SPARFLOXACIN; TACROLIMUS; TERFENADINE; TERODILINE; THIORIDAZINE; UNINDEXED DRUG; VERAPAMIL;

CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; HUMAN; LONG QT SYNDROME; PHARMACODYNAMICS; PHARMACOKINETICS; REVIEW; TORSADE DES POINTES;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY; HUMANS; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; TORSADES DE POINTES; TOXICOLOGY;

EID: 0036234833     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. 1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine
2. Torsades de pointes occuring in association with terfenadine use
3. Drugs that prolong QT interval as an unwanted effect: Assessing their likelihood of inducing hazardous cardiac dysrhythmias
4. Organising evidence on QT prolongation and occurrence of torsades de pointes with non-antiarrhythmic drugs: A call for consensus
5. Pharmacokinetic-pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats
6. The QT interval and torsade de pointes
7. Electrocardiographic assessment of antianxiety medication in dogs and correlation with serum drug concentration
8. The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing
9. QT interval prolongation by non-cardiovascular drugs: Issues and solutions for novel drug development
10. Screening lead compounds for QT interval prolongation
11. + channel HERG
12. + currents in rat ventricular myocytes
13. + currents responsible for repolarization in mouse ventricle and their modulation by FK-506 and rapamycin
14. The potential for QT prolongation and pro-arrhythmia by nonanti-arrhythmic drugs: Clinical and regulatory implications: Report on a Policy Conference of the European Society of Cardiology
15. Molecular biology and the prolonged QT syndromes
16. Blood binding and drug monitoring
17. Pharmacokinetics and pharmacodynamics in toxicology
18. Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog
19. Bioavailability assessment of disopyramide using pharmacokinetic-pharmacodynamic (PK-PD) modelling in the rat
20. Effects of fluoroquinolones on HERG currents
21. Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration
22. Comparison of the erythrocyte partitioning method with two classical methods for estimating free drug fraction in plasma
23. Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man
24. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes
25. The assessment of potential for QT interval prolongation with new pharmaceuticals: Impact on drug development
26. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: Results of an international survey
27. Effects of H, antihistamines on animal models of QTc prolongation
28. Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats
29. A comparative pharmacokinetic-pharmacodynamic study of the electrocardiographic effects of epinastine and terfenadine in rats
30. Sustained QT prolongation induced by tacrolimus in guinea pigs
31. A comparative pharmacodynamic study of the arrhythmogenicity of antidepressants, fluvoxamine and imipramine, in guinea pigs
32. Application of computer-assisted radiotelemetry in the pharmacokinetic and pharmacodynamic modeling of procainamide and N-acetylprocainamide
33. Effect of magnesium sulfate on the haloperidol-induced QT prolongation assessed in the canine in vivo model under the monitoring of monophasic action potential
34. Potentiation of halofantrine-induced QTc prolongation by mefloquine: Correlation with blood concentrations of halofantrine
35. Torsade de pointes with an antihistamine metabolite: Potassium channel blockade with desmethylastemizole
36. The canine Purkinje fiber: An in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis
37. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes
38. Stereoselective halofantrine disposition and effect: Concentration-related QTc prolongation
39. Comparison of the acute cardiotoxicity of the antimalarial drug halofantrine in vitro and in vivo in anaesthetised guinea pigs
40. Inhibition of HERG potassium channels by the antimalarial agent halofantrine
41. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs
42. Studies on serum protein binding of haloperidol
43. + channel by the neuroleptic pimozide
44. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients
45. Blockade of currents by the antimalarial drug chloroquine in feline ventricular myocytes
46. Characterization of chloroquine plasma protein binding in man
47. Inhibition of HERG potassium channel current by the class la antiarrhythmic agent disopyramide
48. 4-receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles
49. Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers
50. A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males
51. The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine
52. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG
53. Sertindole (Serdolect): Preclinical and clinical findings of a new atypical antipsychotic
54. Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose-escalation studies
55. Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial
56. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current
57. In vitro blood distribution of mesoridazine and thioridazine
58. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans
59. Cardiovascular drugs. Dofetilide
60. + currents and action potentials
61. Action potentials, contraction, and membrane currents in guinea pig ventricular preparations treated with the antispasmodic agent terodiline
62. + current by therapeutic concentrations of the antispasmodic agent terodiline
63. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics
64. Safety profile of sparfloxacin, a new fluoroquinolone antibiotic
65. Effect of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval)
66. The cardiac pharmacodynamics of therapeutic doses of sparfloxacin
67. Proarrhythmic effects of fluoroquinolone antibacterial agents: In vivo effects as physiologic substrate for torsades
68. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline
69. + channels by imipramine in guinea pig cardiac ventricular cells
70. + channels involved in long QT syndromes, are targets for calcium channel blockers
71. 2+ channel blocker mibefradil on repolarization of guinea pig, rabbit, dog, monkey, and human cardiac tissue
72. Verapamil: A review of its pharmacological properties and therapeutic use in coronary artery disease
73. Pharmacokinetics of sotalol enantiomers after single and repeated oral administration of sotalol hydrochloride to rats
74. Kr, and effects on myocardial refractoriness for class III antiarrhythmic agents
75. Protein binding of sotalol enantiomers in young and elderly human and rat serum using ultrafiltration
76. Prediction of sotalol-induced maximum steady-state QTc prolongation from single-dose administration in healthy volunteers
77. Tolerance to the repolarization effects of rac-sotalol during long-term treatment
78. Detection and determination of free and plasma proteinbound astemizole by thin-layer chromatography: A useful technique for bioavailability studies
79. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)
80. Fexofenadine: A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria
81. 1-receptor occupancy
82. 'Conventional' antihistamines slow cardiac repolarization in isolated perfused (Langendorff) feline hearts
83. Metabolism of chlorpheniramine maleate in man
84. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential?
85. 14C]-mosapride citrate after a single oral administration in rats, dogs and monkeys
86. 4 receptors in guinea pig ileum
87. Plasma protein binding to tacrolimus in humans
88. Cardiac effects of ebastine and other antihistamines in humans
89. Preclinical in vitro cardiac electrophysiology: A method of predicting arrhythmogenic potential of antihistamines in humans?
90. 14C]ebastine after a single administration in rats
91. + channel family by ebastine
92. The sulphonylurea glibenclamide inhibits voltage dependent potassium currents in human atrial and ventricular myocytes